-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

Benzinga·10/15/2026 21:47:13
语音播报
UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.